CURRENT ASPECTS REGARDING THE RELEVANCE OF INFLAMMATION IN MAJOR DEPRESSIVE DISORDER
Abstract
CURRENT ASPECTS REGARDING THE RELEVANCE OF INFLAMMATION IN MAJOR DEPRESSIVE DISORDER (Abstract): The World Health Organization predicts that depression, which already affects about 10% of the population in the United States, will be the world’s leading medical condition by 2030. The relationship between inflammation and depression has a bidirectional potential, but the underlying mechanisms are still less knowledgeable. In this way, the theory that argues that the inflammatory process is an etiologic factor in depression associated increased levels of inflammatory markers with decreased levels of serotonin, a neurotransmitter important in the pathogenesis of depression. An increase in serum levels of cytokines may lead to decreased availability of serotonin and other neurotransmitters, activation of the hypothalamic-pituitary-adrenal axis and increased oxidative stress in the brain. Depressive symptoms can cause a slight inflammatory response by triggering certain hormonal disorders in the HPA axis that leads to increased susceptibility to infections. Thus, inflammatory mechanisms may provide new paths for intervention and prevention of depressive affective disorders. Also, inflammation could explain the fairly widespread association of somatic-type diseases (such as cardiovascular disease) and diabetes, as well as mental disorders such as depression or schizophrenia. Cytokines have been shown to be related to many depression symptoms to a variety of the population. Examination of gene expression profiles provides insight into how altered gene activity is linked with exposure to stress. The expression of a gene may increase or decrease, and it represents the first step in the production of proteins that communicate changes in cell functions, including those that are involved in the immune systems’ response to the inflammation.
References
2. Kronenberg G, Gertz K, Heintz A, Endres M, of mice and men: modelling post-stroke depression experimentally. British Journal of Pharmacology 2014; 171: 4673-4689.
3. Burton N. Psychiatry. 2nd Edition Acheron Press, 2010: 80-84.
4. Khazaie H, Rezaie L, Payam R, Najafi N. Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone, a randomized controlled trial. General Hospital Psychiatry 2015; 37: 40-45.
5. Brand S, Moller M, Harvey B. A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates. Current Neuropharmacology 2015; 13; 324-368.
6. Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: Diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 2011; 36: 2375-2394.
7. Haapakovsky R, Mathieu J, Allenius H. Cumulative meta-analysis of interleukin 6 and 1b, tumor necrosis alfa and C reactive protein in patients with major depressive disorder. Brain, Behavior and Immunity 2015; 49: 206-215.
8. Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the directionality of the depression-inflammation relationship. Brain Behav Immun 2009; 23(7): 936-944.
9. Davis NJ, Crandall JP, Gajavelli S, Berman JW, Tomuta N, Wylie-Rosett J, Katz SD. Differential effects of low-carbohydrate and low-fat diets on inflammation and endothelial function in diabetes. Journal of Diabetes and its Complications 2011; 25: 371-376.
10. Fang Y, Ross A, Harsh B, Godwin A, Tseng M. Acculturative stress and inflammation among Chinese immigrant women. Psychosom Med 2014; 76(5): 320-326.
11. Azar R, Nolan R, Stewart DE. Listening to the heart-brain talk: Persistent depressive symptoms are associated with hsCRP in apparently healthy individuals at high risk for coronary artery disease. Eur J Prev Cardiol 2012; 19: 857-863.
12. Song BM, Lee J-M, Choi W, et al. Association between C reactive protein level and depressive symptoms in an elderly Korean population: Korean Social Life, Health and Aging Project. BMJ Open 2015; 5: e006429.
13. Spanemberg L, Varres A, Yuri Kawomoto S, Parker G. Biological differences between melancholic and non-melancholic depression subtyped by the CORE measure. Neuropsychiatric Disease and Treatment, 2014; 10: 1523-1531.
14. Franklin N, Adkinson JR, Bruce S. Cytokines in allergic inflammation. In Middleton’s Allergy, Principles and Practice, Mosby Elsevier 7th-Edition 2008, 172.
15. Carter JD, Joyce PR, Mulder RT, Luty SE, McKenzie J. Gender differences in the presentation of depressed outpatients: a comparison of descriptive variables. J Affect Disord 2000; 61: 59-67.
16. Raison CL, Miller AH. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry 2013; 18: 15-37.
17. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358(1): 55-68.
18. Raison LC, Miller AH. Malaise, Melancholia and Madness: The Evolutionary Legacy of an Inflammatory Bias. Brain Behav Immun 2013; 31: 1-8.
19. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70(7): 663-671.
20. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9(1): 46-56.
21. Huffman JC, Celano CM, Januzzi JL. The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes. Neuropsychiatr Dis Treat 2010; 6: 123-136.
22. Leonard BE, Myint AM. Immune dysfunction, depression and neurodegeneration. Acta Neuropsychiatr 2009; 21(Suppl 2): 45-46.
23. Leonard BE, Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol 2009; 24: 165-175.
24. Sprangers A, Thong M, Bartels M, Barsevick A, Biological pathways, candidate genes and molecular markers associated with quality-of-life domains: an update. Qual Life Res 2014; 23(7): 1997-2013.
25. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biological Psychiatry 2010; 67: 446-457.
26. Padurariu M, Lefter R, Ciobica A, Paulet M, Dobrin R, Intraperitoneal oxytocin administration for 9 consecutive days is reducing memory deficits and anxiey in a methionine rat model of schizophrenia. European Neuropsychopharmacology 2016; 26(Suppl 2): 289-290.
27. Balmus IM, Lefter R, Ciobica A, Antioch I, Ababei D, Dobrin R. Preliminary Data on Some Behavioral Changes Induced by Short-Term Intraperitoneal Oxytocin Administration in Aged Rats. Psychiatr Danub 2018; 30(1): 91-98.
28. Golam K, Pearson R, Zammit S, Lewis G, Jones P. Association of Serum Interleukin 6 and C-Reactive Protein in Childhood with Depression and Psychosis in Young Adult Life. JAMA Psychiatry 2014; 71(10): 1121-1128.
29. Shang YX, Ding WQ, Qiu HY, Zhu FP, Yan SZ, Wang XL. Association of depression with inflammation in hospitalized patients of myocardial Infarction. Pak J Med Sci 2014; 30(4): 692-697.
30. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104(3): 365-372.
31. Schins A, Tulner D, Lousberg R, Kenis G, Delanghe J, Crijns HJ, et al. Inflammatory markers in depressed post-myocardial infarction patients. J Psychiatr Res 2005; 39(2): 137-144.
32. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a metaanalysis. Psychosom Med 2009; 71(2): 171-186.
33. Vogelzangs N, Seldenrijk A, Beekman AT, van Hout HP, de JP, Penninx BW. Cardiovascular disease in persons with depressive and anxiety disorders. J Affect Disord 2010; 125(1-3): 241-248.
34. Vogelzangs N, Beekman A, Jonge P, Penninx B. Anxiety disorders and inflammation in a large adult Cohort. Translational Psychiatry 2014; 3: e249.
35. Copeland WE, Shanahan L, Worthman C, Angold A, Costello EJ. Generalized anxiety and C-reactive protein levels: a prospective, longitudinal analysis. Psychol Med 2012; 42: 2641-2650.
36. Pitsavos C, Panagiotakos DB, Papageorgiou C, Tsetsekou E, Soldatos C, Stefanadis C. Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study. Atherosclerosis 2006; 185: 320-326.
37. Livingston S, Heather L, Nersesian P, Baxter T, Mysliwiec V. Improved sleep in military personnel is associated with changes in the expression of inflammatory genes and improvement in depression symp-toms. Frontier in psychiatry 2015; 6: 59.
38. Liukkonen T, Rasanen P, Jokelainen J, Leinonen M, Jarvelin MR, Meyer-Rochow VB, et al. The association between anxiety and C-reactive protein (CRP) levels: results from the Northern Finland 1966 birth cohort study. Eur Psychiatry 2011; 26: 363-369.
39. Arfken CL, Joseph A, Sandhu GR, Roehrs T, Douglass AB, Boutros NN. The status of sleep abnormalities as a diagnostic test for major depressive disorder. J Affect Disord 2014; 156: 36-45.
40. Iorga M, Muraru D, Soponaru C, Petrariu FD. Factors influencing the level of depression among freshman nursing students. Rev. Med. Chir. Soc. Med. Nat. Iasi 2017; 121(4): 779-786.
41. Carter JD, Joyce PR, Mulder RT, Luty SE, McKenzie J. Gender differences in the presentation of depressed outpatients: a comparison of descriptive variables. J Affect Disorder 2000; 61: 59-67.
42. Mui AC, Kang SY. Acculturation stress and depression among Asian immigrant elders. Soc Work 2006; 51: 243-55.
43. Whooley MA, Caska CM, Hendrickson BE, Rourke MA, Ho J, Ali S. Depression and inflammation in patients with coronary heart disease: findings from the Heart and Soul Study. Biol Psychiatry 2007; 62(4): 314-320.
44. Weinberger JF, Raison LC, Rye DB, Montague AR, Woolwine BJ, Felger JC, Haroon E, Miller AH. Inhibition of Tumor Necrosis Factor Improves Sleep Continuity in Patients with Treatment Resistant Depression and High Inflammation. Brain Behav Immun 2015; 47: 193-200.
45. Giles DE, Jarrett RB, Rush AJ, Biggs MM, Roffwarg HP. Prospective assessment of electroencephalo-graphic sleep in remitted major depression. Psychiatry Research 1993; 46: 269- 284.
46. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358(1): 55-68.
47. Illi J, Miaskowski C, Cooper B, Levine JD, Dunn L, West C, et al. Association between pro- and anti-inflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine 2012; 58: 437-447.
48. Bower JE, Ganz PA, Irwin MR, Castellon S, Arevalo J, Cole SW. Cytokine genetic variations and fatigue among patients with breast cancer. Journal of Clinical Oncology 2013; 31(13): 1656-1661.
49. Holtzman S, Abbey SE, Chan C, Bargman JM, Stewart DE. A genetic predisposition to produce low levels of IL-10 is related to depressive symptoms: A pilot study of patients with end stage renal disease. Psychosomatics 2012; 53: 155-161.
50. Schoormans D, Radonic T, de Witte P, Groenink M, Azim D, Lutter R, et al. Mental quality of life is related to a cytokine genetic pathway. Plos One 2012; 7(9): e45126.
51. Kao CF, Fang YS, Zhao Z, Kuo PH. Prioritization and evaluation of depression candidate genes by combining multidimensional data resources. PLoS One 2011; 6(4): e18696.
Additional Files
Published
Issue
Section
License
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form